Login / Signup

Feasibility of high-throughput sequencing in clinical routine cancer care: lessons from the cancer pilot project of the France Genomic Medicine 2025 plan.

null nullCéline AuzanneauDelphine BacqCarine BelleraHélène BlonsAnne BolandMarlène BoucheixAurélien BourdonEmmanuelle CholletChristine ChomienneJean-François DeleuzeChristelle DelmasDerek DinartHélène EspérouFlore GeillonDamien GenesteAntoine ItalianoDelphine JeanEmmanuel KhalifaYec'han LaizetPierre Laurent-PuigFranck LethimonnierClaire Lévy-MarchalCarlo LucchesiCarine MallePierre ManciniSimone Mathoulin-PélissierVincent MeyerPalomares Marie-AngeGéraldine PerkinsSabrina Sellan-AlbertIsabelle SoubeyranCédric Wallet
Published in: ESMO open (2021)
Our results demonstrate the feasibility of tumour genomic analysis by WES/RNASeq within a time frame compatible with the current cancer patient care. Lessons learnt from the Multipli WES/RNASeq Platforms Workflow Study will constitute guidelines for the forthcoming Multipli study and more broadly for the future clinical routine practice in the first two France Genomic Medicine 2025 platforms.
Keyphrases
  • papillary thyroid
  • clinical practice
  • healthcare
  • primary care
  • high throughput sequencing
  • copy number
  • quality improvement
  • randomized controlled trial
  • gene expression
  • young adults
  • childhood cancer